Huntington's Disease News and Research

Latest Huntington's Disease News and Research

GE Healthcare, Tesla Engineering announce collaboration to develop ultra high-field MRI systems

Today at the joint meeting of the International Society for Magnetic Resonance in Medicine and the European Society for Magnetic Resonance in Medicine and Biology, GE Healthcare and Tesla Engineering Ltd. announced that they will collaborate together to produce 7.0 tesla (7.0T) human whole-body magnetic resonance imaging (MRI) scanners, and build upon the ten year history of GE innovations in this advanced, technical field.

12 May 2014

Isis Pharmaceuticals reports pro forma net operating loss of $22.6 million for Q1 2014

Isis Pharmaceuticals, Inc. today reported a pro forma net operating loss (NOL) of $22.6 million for the three months ended March 31, 2014 compared to pro forma operating income of $4.5 million for the same period in 2013.

6 May 2014

Diagnosis of Huntington's disease requires combination of clinical symptoms, radiological changes, genetic diagnosis

Huntington's disease is an autosomal-dominant inherited neurodegenerative disease with a distinct phenotype, but the pathogenesis is unclear.

6 May 2014

AAN review finds certain forms of medical marijuana can help treat some symptoms of MS

A review by the American Academy of Neurology of available scientific research on the use of medical marijuana in brain diseases finds certain forms of medical marijuana can help treat some symptoms of multiple sclerosis (MS), but do not appear to be helpful in treating drug-induced (levodopa) movements in Parkinson's disease.

29 Apr 2014

Interleukin receives conditional approval to offer results of PerioPredict genetic risk test

Interleukin Genetics, Inc. today announced it has received conditional approval from the New York State Department of Health to offer, process and report the results of the PerioPredict™ Genetic Risk Test for periodontal disease.

22 Apr 2014

MSU research pushes promising molecule toward clinical trials for treatment of neurological disorders

The most effective way to tackle debilitating diseases is to punch them at the start and keep them from growing.

22 Apr 2014

New mouse study indicates that mutant protein in muscle cells is responsible for SBMA

Sometimes known as Kennedy's disease, spinal and bulbar muscular atrophy (SBMA) is a rare inherited neuromuscular disorder characterized by slowly progressive muscle weakness and atrophy.

17 Apr 2014

Study evaluates co-occurrence of cancers in patients with central nervous system disorders

The study evaluated the co-occurrence of cancers in patients with central nervous system disorders, including Alzheimer's disease, amyotrophic lateral sclerosis, autism spectrum disorders, Down's syndrome, Huntington's disease, multiple sclerosis, Parkinson's disease and schizophrenia.

15 Apr 2014

Thomson Reuters, Children's Tumor Foundation partner to create neurofibromatosis pathway maps

The Intellectual Property & Science business of Thomson Reuters, the world's leading provider of intelligent information for businesses and professionals, today announced an expansion of its partnership with the Children's Tumor Foundation to create unique neurofibromatosis (NF) pathway maps aimed at significantly increasing the understanding of the disease and its underlying mechanisms.

4 Apr 2014

FDA clears Omeros' OMS721 IND for inhibition of complement‑mediated TMAs

Omeros Corporation today announced that its Investigational New Drug Application (IND) to evaluate OMS721 for the inhibition of complement‑mediated thrombotic microangiopathies (TMAs) has been cleared by the U.S. Food and Drug Administration.

3 Apr 2014

Expert in gene therapy joins The Children's Hospital of Philadelphia

Beverly L. Davidson, Ph.D., a nationally prominent expert in gene therapy, is joining The Children's Hospital of Philadelphia (CHOP) today.

2 Apr 2014

Prana Biotechnology releases top-line results of PBT2 Phase II Imaging trial in Alzheimer's disease

Prana Biotechnology has today released the top line results of the 12-month Phase II Imaging trial in Alzheimer's Disease ("IMAGINE" Trial), based on draft results.

31 Mar 2014

New gene-editing system holds potential for treating many genetic disorders

Using a new gene-editing system based on bacterial proteins, MIT researchers have cured mice of a rare liver disorder caused by a single genetic mutation.

31 Mar 2014

Potassium boost improves walking, prolongs survival in mouse model of Huntington's disease

Tweaking a specific cell type's ability to absorb potassium in the brain improved walking and prolonged survival in a mouse model of Huntington's disease, reports a UCLA study published March 30 in the online edition of Nature Neuroscience. The discovery could point to new drug targets for treating the devastating disease, which strikes one in every 20,000 Americans.

31 Mar 2014

Johns Hopkins neuroscientists identify cause of brain degeneration in Huntington's disease

Working with genetically engineered mice, Johns Hopkins neuroscientists report they have identified what they believe is the cause of the vast disintegration of a part of the brain called the corpus striatum in rodents and people with Huntington's disease: loss of the ability to make the amino acid cysteine.

29 Mar 2014

FDA accepts Lundbeck's carbamazepine NDA for review

Lundbeck LLC today announced that the U.S. Food and Drug Administration has accepted for review a New Drug Application (NDA) for its investigational therapy intravenous carbamazepine, an intravenous formulation of the anti-epileptic drug (AED) carbamazepine. An action letter is anticipated before the end of 2014. Carbella is the proposed U.S. trade name for intravenous carbamazepine.

10 Mar 2014

Omeros submits investigational new drug to initiate OMS721 Phase 2 clinical program

Omeros Corporation today announced that it has submitted to the U.S. Food and Drug Administration (FDA) an investigational new drug (IND) application to initiate the Phase 2 clinical program for OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin‑associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system.

4 Mar 2014

Protein interaction network provides invaluable resource to identify targets for Huntington's disease

Researchers at the Buck Institute have identified and categorized thousands of protein interactions involving huntingtin, the protein responsible for Huntington's disease (HD). To use an analogy of a human social network, the identified proteins are like "friends" and "friends of friends" of the HD protein.

28 Feb 2014

Study provides novel insight into the impact of genes on Huntington's disease

A study led by researchers at Boston University School of Medicine provides novel insight into the impact that genes may have on Huntington's disease (HD). The study, published online in PLOS Genetics, identified specific small segments of RNA (called micro RNA or miRNA) encoded in DNA in the human genome that are highly expressed in HD.

27 Feb 2014

Researchers develop new compound that slows down progression of Huntington's Disease

Juliet Ross is suffering from Huntington's Disease, a rare neurological disorder that affects one in 10.000 people. Due to a genetic defect, her body produces a toxic protein that damages neurons in her brain.

26 Feb 2014

Huntington's Disease News and Research

Latest Huntington's Disease News and Research

GE Healthcare, Tesla Engineering announce collaboration to develop ultra high-field MRI systems

Isis Pharmaceuticals reports pro forma net operating loss of $22.6 million for Q1 2014

Diagnosis of Huntington's disease requires combination of clinical symptoms, radiological changes, genetic diagnosis

AAN review finds certain forms of medical marijuana can help treat some symptoms of MS

Interleukin receives conditional approval to offer results of PerioPredict genetic risk test

MSU research pushes promising molecule toward clinical trials for treatment of neurological disorders

New mouse study indicates that mutant protein in muscle cells is responsible for SBMA

Study evaluates co-occurrence of cancers in patients with central nervous system disorders

Thomson Reuters, Children's Tumor Foundation partner to create neurofibromatosis pathway maps

FDA clears Omeros' OMS721 IND for inhibition of complement‑mediated TMAs

Expert in gene therapy joins The Children's Hospital of Philadelphia

Prana Biotechnology releases top-line results of PBT2 Phase II Imaging trial in Alzheimer's disease

New gene-editing system holds potential for treating many genetic disorders

Potassium boost improves walking, prolongs survival in mouse model of Huntington's disease

Johns Hopkins neuroscientists identify cause of brain degeneration in Huntington's disease

FDA accepts Lundbeck's carbamazepine NDA for review

Omeros submits investigational new drug to initiate OMS721 Phase 2 clinical program

Protein interaction network provides invaluable resource to identify targets for Huntington's disease

Study provides novel insight into the impact of genes on Huntington's disease

Researchers develop new compound that slows down progression of Huntington's Disease

eBook: Advancing neurodegenerative research with iPSC-derived microglia models eBook

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Huntington's Disease News and Research

Latest Huntington's Disease News and Research

eBook: Advancing neurodegenerative research with iPSC-derived microglia models eBook

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in